This discordance between the functions of HADC inhibitors and HAT inhibitors implicates the complexity of the regulation of the important epigenetic modification, i.e., histone acetylation, to the anticancer activity of genotoxic drugs such as cisplatin, suggesting that the balance of epigenetic modification status plays a crucial role in cancer therapy. The gene discussed is TMPRSS11D; the disease is cancer.